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Edited by Hans EklundAbstract The substrate spectrum of human thioredoxin reduc-
tase (hTrxR) is attributed to its C-terminal extension of 16 ami-
no acids carrying a selenocysteine residue. The concept of an
evolutionary link between thioredoxin reductase and glutathione
reductase (GR) is presently discussed and supported by the fact
that almost all residues at catalytic and substrate recognition
sites are identical. Here, we addressed the question if a deletion
of the C-terminal part of TrxR leads to recognition of glutathi-
one disulﬁde (GSSG), the substrate of GR. We introduced muta-
tions at the putative substrate binding site to enhance GSSG
binding and turnover. However, none of these enzyme species ac-
cepted GSSG as substrate better than the full length cysteine
mutant of TrxR, excluding a role of the C-terminal extension
in preventing GSSG binding. Furthermore, we show that GSSG
binding at the N-terminal active site of TrxR is electrostatically
disfavoured.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The intracellular redox milieu is supported by the thiore-
doxin system, composed of the ﬂavoenzyme thioredoxin reduc-
tase (TrxR, EC 1.8.1.9), NADPH and its main substrate
thioredoxin (Trx). TrxR catalyzes the NADPH-dependent
reduction of Trx disulﬁde (Trx(S)2). This reaction is comprised
of several steps including the transfer of electrons from
NADPH to FAD, from FAD to the N-terminally located ac-
tive site disulﬁde and subsequently to a second redox center lo-
cated on the ﬂexible C-terminal end of the other subunit.
During catalysis, this C-terminal arm acts as an electron shut-
tle between the buried N-terminal active site and the substrate
[1–3]. TrxR regulates a variety of cellular processes, indirectlyAbbreviations: aa, amino acid; bp, base pair(s); DTNB, 5,50-dithi-
obis(2-nitrobenzoic acid); eq., equivalents; GSH, reduced glutathione;
GSSG, oxidized glutathione; hGR, human glutathione reductase;
hTrxR1, human thioredoxin reductase 1; rTrxR1, rat thioredoxin
reductase 1; dmTrxR1, Drosophila melanogaster TrxR1; Sec, seleno-
cysteine; Trx, thioredoxin; TrxR1, cytosolic thioredoxin reductase;
TrxR2, mitochondrial thioredoxin reductase; U, selenocysteine
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strates acting in DNA and selenium metabolism, antioxidant
defence and cell growth regulation [4,5]. Inhibition of TrxR
or Trx in human malignoma such as glioblastoma, colon can-
cer, lung and breast cancer is a most promising approach to
chemotherapy via redox targeting [6–8].
In parallel with the thioredoxin system, the glutathione sys-
tem comprising glutathione reductase (GR, EC 1.8.1.7),
NADPH, the tripeptide glutathione (GSH) and glutaredoxin
(Grx) is essentially involved in cellular redox-regulation. GR
catalyzes the NADPH-dependent reduction of glutathione
disulﬁde (GSSG) to GSH and belongs, like TrxR, to the family
of homodimeric pyridine nucleotide-disulﬁde oxidoreductases
[9].
Recent ﬁndings support a common evolution of the two re-
dox enzymes. First, large TrxRs resemble eukaryotic GRs
rather than small (or prokaryotic) TrxRs and second, a coex-
istence of large TrxRs and small TrxRs, which do not possess
the C-terminal prolongation, in the same organism could be
shown. Phylogenetic analyses revealed that large TrxRs might
have derived from GRs of lower eukaryotes by carboxytermi-
nal elongation or that, vice versa, carboxyterminal shortenings
of extensions may occur in evolution [10].
In addition, a link between the Trx and GSH system is rep-
resented by the recently described thioredoxin glutathione
reductase (TGR). Possessing an N-terminal Grx domain in
addition to the C-terminal selenocysteine-containing redox
center, this TrxR-GR chimeric enzyme exerts TrxR, GR and
Grx activities [11].
Structure, reaction mechanism and substrate recognition
of GR have been studied in detail [12,13]. These data to-
gether with the mechanistic studies ([2,14,15]; reviewed in
[5]) and the crystal structure of the rat thioredoxin reductase
mutant (Secﬁ Cys) in complex with NADP+ [16] indicated
that large TrxR and human glutathione reductase (hGR)
share very similar cofactor and substrate binding sites. Most
amino acid residues responsible for GSSG interaction in GR
are conserved in TrxR, but the latter possesses a 16 aa long
C-terminal extension. It was hypothesized that this ﬂexible
arm hinders proper binding of GSSG to the N-terminal ac-
tive site. A truncated TrxR should thus possess GR-activity
[16].
Here, we studied human thioredoxin reductase 1 (TrxR1)
lacking the last 16 C-terminal amino acids as well as a number
of mutants of this protein. Substrate speciﬁcity and catalytic
properties of these enzyme species were determined and the
electrostatic potentials of the substrate binding region were
calculated.blished by Elsevier B.V. All rights reserved.
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2.1. Molecular modeling
Structural models containing mutated residues of hTrxR were built
using the programs O [20] and CNS [21] on the basis of available struc-
ture data for human GR (PDB code 1gra) and rat TrxR (PDB code
1h6v). Charge analyses of the dimer surfaces were carried out using
the graphic program Grasp [22].
2.2. Generation, expression and puriﬁcation of hTrxR mutants (hTrxR-
16, hTrxR-16K29R, hTrxR-16K29RH108Y, hTrxR-16K29RH108YA119N,
hTrxR-16K29RH108YA119NV478E, and hTrxRU498C)
The initial steps were performed following established protocols as
detailed in the article’s supplement on the FEBS Letters homepage.
Brieﬂy, the TrxR gene lacking the last 48 bp was cloned into the
pET28a(+) expression vector (Novagen) and additional mutations
were introduced by site-directed mutagenesis. After transformation
into BL21 Rosetta (DE3)pLysS E. coli cells, expression at 30–37 C
and protein extraction, the proteins were puriﬁed using a Ni-NTA
resin according to QIAexpressionist (Qiagen).
2.3. Protein concentration and FAD contents
The extinction coeﬃcient of FAD-containing subunits was deter-
mined for all hTrxR mutants at high concentrations based on their
absorbance at 463 nm and compared to e = 11.3 mM1 cm1 for wild-
type TrxR [2,3]. In parallel, Bradford assays for determination of pro-
tein acidic groups with Coomassie Brilliant Blue G-250 at 595 nm were
applied. Extinction coeﬃcients of 98 mM1 cm1 (hTrxR-16, hTrxR-
16K29R) and 99.2 mM1 cm1 (hTrxR-16K29RH108Y, hTrxR-
16K29RH108YA119N, hTrxR-16K29RH108YA119NV478E), respectively, were
determined at 280 nm.
2.4. Titrations with NADPH
Oxidised and NADPH reduced (0, 3, 7.5, 10, 15, 30, 45, 75 and
90 lM NADPH) absorption spectra of hTrxR-16 and hTrxRU498C
mutants (15 lM) were recorded (250–800 nm) at 25 C under aerobic
conditions using a Hitachi U-2100 UV-visual spectrophotometer and
analysed using KaleidaGraph (Synergy Software).
2.5. Kinetic characterization of the TrxR mutants
TrxR activity was measured using 5,5 0-dithiobis(2-nitrobenzoic acid)
(DTNB) [17] as well as a Trx mutant (hTrxC73S) [18] as substrates.
The NADPH-dependent reduction of DTNB/Trx in 100 mM phos-
phate buﬀer, 1 mM EDTA, pH 7.4 was determined as the increase/de-
crease in absorbance at 412 nm/340 nm at 25 C (e412 nm = 13.6 mM1
cm1; e340 nm = 6.22 mM
1 cm1). GR activity was measured using
GSSG [19]. Reaction mixtures (0.5 ml) contained up to 5 lM TrxR
mutant and 100 lM NADPH in 47 mM phosphate buﬀer, 1 mM
EDTA, 100 mM KCl, pH 6.9. Kinetic analysis were done using
0–50 mMGSSG. A reference cuvette containing all components except
for GSSG was used to correct for NADPH oxidase activity.3. Results and discussion
Mammalian TrxR and GR share many common features
such as a similar overall structure, the location of active sites,
cofactor and substrate binding sites, a high similarity of active
site residues, and similar reaction mechanism with respect to
the reductive half-reaction. Substrate binding and dissociation
follow a ping-pong mechanism and most residues forming
hydrogen bonds with GSSG have corresponding partners in
TrxR with very few substitutions (R38K, E473V) (Fig. 1)
[13,16]. The major feature distinguishing TrxR from GR is
the C-terminal extension with a cysteine-selenocysteine-
containing second redox active site [23]. This mobile reduction
site enables the acceptance of diﬀerent substrates. Some small
substrates like DTNB, however, have additional access to the
N-terminal active site cysteines and can be reduced there[24,25]. DTNB was also shown to be accepted by GR under
certain conditions [26]. This constellation led to the hypothesis
that in a truncated TrxR lacking the last 16 amino acids the
access of the N-terminal active site might be facilitated allow-
ing the reduction of GSSG [16].
To study this hypothesis, we deleted the C-terminal part of
hTrxR-1 (hTrxR-16). A comparison of the putative GSSG
binding sites of hGR and hTrxR (Fig. 1) clearly identiﬁed
the major substitutions in hTrxR (marked in red in Fig. 1B)
which were chosen as target sites to enhance GSSG binding.
In GR the carboxyl groups of glutamate I (ﬁrst half of
GSSG) are anchored by two arginines, R37 and R347, the
corresponding residues in TrxR being K29 and R351. The
polypeptide chains in these regions follow very similar courses
in the two enzymes. Thus, K29 was changed to R in order to
allow the formation of a salt-bridge with the carboxylate of
glycine I of GSSG and a conformational change upon GSSG
binding as demonstrated for R37. The side chains of R351 in
rat TrxR (rTrxR) and R347 in hGR have a diﬀerent orienta-
tion since the side chain of R351 is hydrogen bonded to
Q348. Furthermore, the close proximity of E30 to R351 is
likely to allow a salt bridge or, in case of GSSG binding,
the amino groups of R351 should be available to ﬁx the carb-
oxyterminal tail of GSSG in a salt-bridge (Fig. 1B). In GR
the c-carboxyl group of glutamate II (second half of GSSG)
interacts with the backbone atoms of residues 406 0 and 469 0.
E472 0 and E473 0 form ionic interactions with the a-amino
group of c-carboxyl group and the carboxylate of glycine II
is ﬁxed by N117 [13]. The stereochemical modeling of GSSG
in complex with rTrxR suggests to change the residues corre-
sponding to E473 and N117 of hGR to create a similar bind-
ing site architecture in TrxR (Fig. 1B). V478 of the second
hTrxR subunit was furthermore changed to E and A119 to
N.
Finally, H108 was changed to Y since the distance of the
corresponding Y106 of hGR from GSSG is only 4.3 A˚ and
allows hydrogen bonding with a cysteinyl residue thereof. Re-
cent ﬁndings indicate that H108 of large TrxR does not act as
base-catalyst, supporting that our mutagenesis does not aﬀect
catalysis [27]. Fig. 1B clearly shows that, together with the cho-
sen mutations, the TrxR–GSSG model is in good agreement
with that of the GR–GSSG complex.
On the basis of these data, four hTrxR mutants were created
(hTrxR-16, hTrxR-16K29R, hTrxR-16K29R,H108Y and hTrxR-
16K29R,H108Y,A119N,V478E). We obtained moderate levels of
pure and yellow, enzymatically active hTrxR-16. All other mu-
tants where colorless to bright yellow which was reﬂected by
spectral changes (<50% of the A463 nm absorbance of the
wild-type enzyme). Thus, 100 lM FAD was used for comple-
mentation before protein puriﬁcation to obtain active holoen-
zymes. After the addition of the prosthetic group, the yellow
color of the holoenzymes remained stable, indicating interac-
tion of FAD with the protein. Absorption ratios A280 nm/
A463 nm as well as extinction coeﬃcients of the oxidized enzyme
species at 463 nm were determined from spectral analyses (wild
type hTrxR: e = 11.3 mM1 cm1 [2,3], hTrxR-16K29R:
e = 11.74 mM1 cm1, hTrxRD16K29R,H108Y: e = 13.87 mM1
cm1, hTrxRD16K29R,H108Y,A119N,V478E: e = 15.22 mM1 cm1).
Oxidised hTrxR-16 had a typical ﬂavoprotein spectrum [28]
with peak absorption at 463 nm (Fig. 2A). Aerobic titrations
with 0.2–6 eq. NADPH led to a blue shift (463ﬁ 450 nm) of
the maximum and the formation of the thiolate-ﬂavin charge
Fig. 1. Structural comparison of TrxR and GR. (A) Primary structure, partial ClustalW (1.83) alignment of some large TrxRs and human GR (the
aa numbering of hGR diﬀers from other published alignments as the ﬁrst methionine is included, but the established numbering is maintained in the
text): amino acids in grey parts belong to the FAD binding domain of rat TrxR1; yellow boxes contain similar amino acids in TrxR and GR with
respect to the GSSG binding sites of hGR; residues in blue boxes belong to the FAD binding domain of hGR. Red amino acids diﬀering between
human thioredoxin reductase 1 (hTrxR1) and hGR have been used for mutagenesis in this work. The C-terminal parts of large TrxR wild-types are
shown in italics. Protein accession numbers (NCBI): hTrxR1, NP_003321; rat thioredoxin reductase 1, AAC35244; Drosophila melanogaster TrxR1,
dmTrxR1 AAG25639; hTrxR2, AAD51324; hGR, RDHUU. (B) 3D-model of amino acid orientation at the active sites of GR and TrxR. GSSG
binding site of hGR (blue aa residues and backbone) and the corresponding region in hTrxR (red aa residues and backbone) possessing the
substitution I478V compared to rTrxR; noteworthy, hTrxR2 keeps the negatively charged glutamate at this position (see A). The interactions
between GSSG (yellow) and the corresponding amino acids are indicated by broken lines.
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Fig. 2. Spectral and kinetic characterization of hTrxR-16. (A) Aerobic titration of 15 lM freshly prepared hTrxR-16 with 0–6 eq. of NADPH (1–9).
(B)–(C) Non-linear regression analysis of Michaelis–Menten kinetics for NADPH (1–100 lM) as well as DTNB (0–10 mM) consumption using
500 nM and 150 nM hTrxR-16, respectively (KM, NADPH = 5.9 ± 1 lM, kcat,NADPH = 17.8 ± 2.7 min
1; KM,DTNB = 2.9 ± 0.6 mM, kcat,DTNB =
33 ± 4 min1). (D) Linear regression analysis of GSSG reduction (1–50 mM GSSG) with 5 lM hTrxR-16 (substrate saturation is not reached).
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540 nm (Fig. 2A).
In previous studies it was proved by site-directed mutagene-
sis that the C-terminal selenocysteine residue of TrxR is not
essential for FAD binding [29]. This ﬁnding was also sup-
ported by our results. It was, however, interesting to see that
already the single mutation of lysine to arginine in the mutant
K29R (Fig. 1B) signiﬁcantly reduced FAD binding. The FAD
binding site is at least 14 A˚ away from the mutation and all
amino acid residues directly involved in FAD binding are in-
tact. A substoichiometric FAD incorporation was observed
earlier for other TrxR mutants [25,30]. All our TrxR mutants
were fully saturated with FAD after complementation as dem-
onstrated by titration spectra and formation of the CT com-
plex similar to those of the wild type after complementation.
The truncated mutants were tested for substrate speciﬁcity
using NADPH, Trx, DTNB as well as GSSG (Table 1). Theaﬃnities for NADPH (Fig. 2B) as reducing substrate were
comparable with the wild-type enzyme for all enzyme species.
As expected, none of the truncated mutants exhibited Trx-
reducing activity since this substrate requires the C-terminal
Cys-Sec redox center for turnover. In all truncated enzyme
species as well as in hTrxRU498C reduction of the small Mr
substrate DTNB (Fig. 2C) followed Michaelis–Menten kinet-
ics with KM values increased by a factor of 10–20 when
compared with the wild-type hTrxR and similar values
when compared with hGR (Table 1 and Ref. [26]). The
catalytic eﬃciency of the quadruple mutant hTrxR-
16K29R,H108Y,A119N,V478E was approximately a third of that
of the single mutant. At concentrations higher than 10 mM
DTNB, substrate inhibition became considerable. For detect-
ing enzymatic reactions of the mutants with GSSG high
TrxR concentrations of 5 lM had to be applied. Even at
50 mM GSSG (where GSSG solubility becomes limited)
Table 1
Substrate speciﬁcity and apparent kinetic parameters of wild type and mutant forms of human thioredoxin reductase
Enzyme variants DTNB NADPH GSSG
KM
(mM)
kcat
(min1)
kcat/KM
(M1 min1)
KM
(lM)
KM
(mM)
kcat
(min1)
Speciﬁc activitya
(lmol min1 mg1)
hTrxR 1 (placenta) 0.088 2000 2.3 · 107 6 nd nd nd
hTrxR-16 2.4 33 1.4 · 104 4.9 nd nd 0.025
hTrxR-16K29R 3.3 31 9.4 · 103 3.4 nd nd 0.016
hTrxR-16K29R,H108Y 4.5 46 1.0 · 104 6.2 nd nd 0.007
hTrxR-16K29R,H108Y,A119N,V478E 1.1 5.3 4.8 · 103 nd nd nd 0.003
hTrxRU498C 0.7 17 2.4 · 104 6 nd nd 0.035
hGR [19,26,27] 2 356b 1.8 · 105 6.6 0.066 8900 200
Values are mean values from at least two independent determinations.
aMeasured at a ﬁxed concentration of GSSG (30 mM).
b4% of kcat for GSSG reduction (as mentioned for maximal velocity in Ref. [2]); nd, not determined.
Fig. 3. Molecular surface of rTrxR (A) and hGR (B) coded by
electrostatic potential [33]. The view is directly into the active site and
GSSG is present in a bond representation. For calculations, the dimer
molecule was used. In TrxR, the last 16 aa residues were not included
in the model.
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for the truncated hTrxR mutants could neither be ﬁtted to ki-
netic models nor were KM and kcat values determined (Table
1). To make a comparison of the mutants possible, speciﬁc
activities were determined at a ﬁxed GSSG concentration of
30 mM. Under these conditions, a substrate turnover of
1.4 min1 for hTrxR-16 and of 0.2 min1 for hTrxR-
16K29R,H108Y,A119N,V478E were calculated from the speciﬁc
activities. When testing the cysteine mutant of hTrxR
(hTrxRU498C) under the same conditions, we detected a 1.4-
fold higher GSSG turnover than for the truncated hTrxR-
16. This value contrasts with earlier ﬁndings where no such
activity could be found for the rat homologue (rTrxRU498C)
[25,29].
In a sphere around the SG-atom of glutamate II with a ra-
dius of 15 A˚, we found 15 positive charges and 10 negative
charges in GR, but only 10 positive and 10 negative charges
in rTrxR-16. The sequence-alignment of rTrxR and hTrxR re-
vealed 11 positive and 11 negative charges in this sphere. Thus,
the charge distribution of rTrxR and hTrxR should be similar
in this region.
Considering the kinetic ﬁndings described above and the fact
that we changed polar aa residues in hTrxR we decided to
compare the electrostatic potentials of the hGR/GSSG com-
plex and a rTrxR–16/GSSG model (Fig. 3). Surprisingly, the
surface around the GSSG binding pocket is much more nega-
tive in rTrxR-16 (Fig. 3A) than in hGR (Fig. 3B). This diﬀer-
ence in charge is most likely to be responsible for a lack of
binding of the negatively charged GSSG to TrxR. The diﬀer-
ence is even more pronounced when including the additional
point mutations in our calculations for rTrxR-16, especially
I478E (data not shown), leading to the even lower GSSG
reducing activity of hTrxR-16K29R,H108Y,A119N,V478E. Further-
more, deletion of the C-terminal part also leads to a small
change in charge distribution at the molecule’s surface. This
may be the reason for the higher reactivity of the full length
cysteine mutant of hTrxR towards GSSG compared to
hTrxR-16.
In conclusion, the hypothesis of Sandalova et al. [16] that a
cleavage of the C-terminal prolongation of mammalian TrxR
might allow the enzyme to act as glutathione reductase, is
clearly disproved by our results. However, the C-terminal
Cys-Sec redox site was unambiguously shown to represent
the unique reaction center for Trx. Results from NADPH
spectra and DTNB assays demonstrate that the truncated
hTrxR-16 mutants indeed are functional proteins and thatthe lack of GSSG reducing activity at catalytic rates is due
to the lack of electrostatic attraction in the potential GSSG
binding pocket.
The molecular diﬀerences between TrxR and GR are more
intricate than previously expected and cannot be overcome
by simple mutagenesis. In addition to the C-terminal diﬀer-
ences, the ﬁrst 17 amino acid residues of hGR are ﬂexible
and are thus not visible in the crystal structure. This N-termi-
nal extension of hGR contains Cys3 as potentially active thiol
which might be involved in GR regulation or attachment to
other structures [12]. Although the three-dimensional struc-
3600 S. Urig et al. / FEBS Letters 580 (2006) 3595–3600tures of rat TrxR-1 [16] and mouse TrxR-2 [31] are now avail-
able, further insights into reaction mechanisms and substrate
interactions are essential to fully understand evolutionary
and functional relations between disulﬁde reductases [32].
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